The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
Open accessAbstract
BACKGROUND: Tuberculosis regimens that are shorter and simpler than the current 6-month daily regimen are needed. METHODS: We randomly assigned patients with newly diagnosed, smear-positive, drug-sensitive tuberculosis to one of three regimens: a control regimen that included 2 months of ethambutol, isoniazid, rifampicin, and pyrazinamide administered daily followed by 4 months of daily isoniazid and rifampicin; a 4-month regimen in which the isoniazid in the control regimen was replaced by moxifloxacin administered daily for 2 months followed by moxifloxacin and 900 mg of rifapentine administered twice weekly for 2 months; or a 6-month regimen in which isoniazid was replaced by daily moxifloxacin for 2 months followed by one weekly dose of both moxifloxacin and 1200 mg of rifapentine for 4 months. Sputum specimens were examined on microscopy and after culture at regular intervals. The primary end point was a composite treatment failure and relapse, with noninferiority based on a margin of 6 percentage points and 90% confidence intervals. RESULTS: We enrolled a total of 827 patients from South Africa, Zimbabwe, Botswana, and Zambia; 28% of patients were coinfected with the human immunodefiency virus. In the per-protocol analysis, the proportion of patients with an unfavorable response was 4.9% in the control group, 3.2% in the 6-month group (adjusted difference from control, -1.8 percentage points; 90% confidence interval [CI], -6.1 to 2.4), and 18.2% in the 4-month group (adjusted difference from control, 13.6 percentage points; 90% CI, 8.1 to 19.1). In the modified intention-to-treat analysis these proportions were 14.4% in the control group, 13.7% in the 6-month group (adjusted difference from control, 0.4 percentage points; 90% CI, -4.7 to 5.6), and 26.9% in the 4-month group (adjusted difference from control, 13.1 percentage points; 90% CI, 6.8 to 19.4). CONCLUSIONS: The 6-month regimen that included weekly administration of high-dose rifapentine and moxifloxacin was as effective as the control regimen. The 4-month regimen was not noninferior to the control regimen. (Funded by the European and Developing Countries Clinical Trials Partnership and the Wellcome Trust; RIFAQUIN Current Controlled Trials number, ISRCTN44153044.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sample Size Tables for Clinical Studies
Machin, D., Campbell, M. J., Tan, S. B., & Tan, S. H. (2008) · Wiley eBooks · doi:10.1002/9781444300710 · Cited by 1,336
Fox, W., Ellard, G. A., & Mitchison, D. A. (1999) · PubMed · Cited by 797
Self-citationBaber, N. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb05705.x · Cited by 759
Statistical Principles for Clinical Trials
Kay, R. (1998) · Journal of International Medical Research · doi:10.1177/030006059802600201 · Cited by 573
Combination Antifungal Therapy for Cryptococcal Meningitis
Day, J. N., Chau, T. T. H., Wolbers, M., Mai, P. P., Dung, N. T., Mai, N. H., Phu, N. H., Nghia, H. D., Phong, N. D., Thai, C. Q., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1110404 · Cited by 545
Cytological and Transcript Analyses Reveal Fat and Lazy Persister-Like Bacilli in Tuberculous Sputum
Garton, N. J., Waddell, S. J., Sherratt, A. L., Lee, S.-M., Smith, R. J., Senner, C., Hinds, J., Rajakumar, K., Adegbola, R. A., Besra, G. S., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050075 · Cited by 435
Self-citationMultiplicity in randomised trials I: endpoints and treatments
Schulz, K. F., & Grimes, D. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66461-6 · Cited by 366
Multiplicity in randomised trials II: subgroup and interim analyses
Schulz, K. F., & Grimes, D. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66516-6 · Cited by 357
Vernon, A., Burman, W., Benator, D., Khan, A., & Bozeman, L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11467-8 · Cited by 308
Dorman, S. E., Johnson, J. L., Goldberg, S., Muzanye, G., Padayatchi, N., Bozeman, L., Heilig, C. M., Bernardo, J., Choudhri, S., Grosset, J. H., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200901-0078oc · Cited by 264
Jindani, A., Nunn, A., & Enarson, D. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17141-9 · Cited by 238
Self-citationPractical Guidelines for Multiplicity Adjustment in Clinical Trials
Proschan, M. A., & Waclawiw, M. A. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00106-9 · Cited by 225
Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model
Rosenthal, I. M., Zhang, M., Williams, K. N., Peloquin, C. A., Tyagi, S., Vernon, A. A., Bishai, W. R., Chaisson, R. E., Grosset, J. H., & Nuermberger, E. L. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040344 · Cited by 205
Timing of relapse in short-course chemotherapy trials for tuberculosis.
Nunn, A., Phillips, P. P. J., & Mitchison, D. A. (2010) · PubMed · Cited by 90
Self-citationDawson, R., Masuka, P., Edwards, D., Bateman, E. D., Bekker, L., Wood, R., & Lawn, S. D. (2010) · PubMed · Cited by 87
den Boon, S., Bateman, E. D., Enarson, D. A., Borgdorff, M. W., Verver, S., Lombard, C. J., Irusen, E. M., Beyers, N., & White, N. W. (2005) · PubMed · Cited by 86
Tam, C. M., Chan, S. L., Chak Wah, L. A. M., et al. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.6.9707037 · Cited by 64
Merle, C. S., Sismanidis, C., Bah-Sow, O. Y., Gninafon, M., Horton, J. D., Lapujade, O., Lo, M. B., Mitchinson, D. A., Perronne, C., Portaels, F., et al. (2012) · Trials · doi:10.1186/1745-6215-13-61 · Cited by 34
Cited by
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., Mendel, C. M., Egizi, E., Moreira, J., Timm, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1901814 · Cited by 1,044
Self-citationFurin, J., Cox, H., & Pai, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30308-3 · Cited by 873
Dheda, K., Barry, C. E., & Maartens, G. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00151-8 · Cited by 599
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
Dorman, S. E., Nahid, P., Kurbatova, E. V., Phillips, P. P. J., Bryant, K., Dooley, K. E., Engle, M., Goldberg, S. V., Phan, H. T. T., Hakim, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2033400 · Cited by 539
Self-citation
Metadata
- Authors
- Jindani, A., Harrison, T. S., Nunn, A. J., Phillips, P. P. J., Churchyard, G. J., Charalambous, S., Hatherill, M., Geldenhuys, H., McIlleron, H. M., Zvada, S. P., Mungofa, S., Shah, N. A., Zizhou, S., Magweta, L., Shepherd, J., Nyirenda, S., van Dijk, J. H., Clouting, H. E., Coleman, D., Bateson, A. L. E., McHugh, T. D., Butcher, P. D., & Mitchison, D. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-10-23
- Volume
- 371
- Issue
- 17
- Pages
- 1599-1608
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2111276287
- Cited by
- 432
- References
- 19
- FWCI
- 35.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.